Profitability Metrics

Gross Margin
100.00%
Operating Margin
81.89%
Net Margin
12.90%

Efficiency Metrics

Revenue per Expense Ratio
5.45
R&D as % of Revenue
0.00%

Earnings Quality

EBITDA Margin
-36.03%
Income Tax Rate
0.00%
EPS
0.1200000000

Balance Sheet Analysis

Current Ratio
2.80
Cash Ratio
1.23
Working Capital
$83.28M
Debt to Equity
0.00
Debt to Assets
0.06%
Equity Ratio
57.21%

Cash Flow Analysis

Operating Cash Flow Ratio
90.16%
Free Cash Flow Ratio
90.16%
CapEx to Revenue
0.00%
Dividends Paid
$133.95M
Stock Buybacks
$193.95M
Total Shareholder Returns
$327.90M
Cash Position Change
-100.00%

Key Takeaways (2023 FY)

  • Maintained positive net income growth despite revenue changes
  • Increased R&D investment by 100.00%

Detailed Growth Metrics

Core Performance

Revenue
125.52%
Net Income
103.24%
EPS
103.37%
Operating Income
121.22%

Operational Efficiency

R&D Expenses
100.00%
SG&A Expenses
223.85%
Operating Cash Flow
-24.74%
Free Cash Flow
-24.74%

Balance Sheet Health

Assets
-5.37%
Debt
-88.61%
Book Value per Share
-2.81%
Inventory
-100.00%

Shareholder Returns

Dividends per Share
-32.69%
Shares Outstanding
-0.01%

Long Term Trends

3Y Revenue/Share
41.05%
5Y Revenue/Share
601.84%
3Y Dividend/Share
-31.27%
5Y Dividend/Share
-34.34%